drugset / Trial / NCT05931744
The Role of Budesonide Intrapolyp Injection in the Management of Type 2 Chronic Rhinosinusitis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To investigate the usage of budesonide as an agent in the injection of Type 2 chronic rhinosinusitis with nasal polyps
Timeline
- Start
- 2021-05-01
- Primary completion
- 2023-02-01
- Completion
- 2023-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Budesonide | Small molecule | 0.5 mg | Other |
| Comparator | Prednisone | Other / unclassified | 1 mg/kg | Oral |